Comparison of 23-Valent Pneumococcal IgG ELISA with Multiplex 13-Valent Serotype-Specific Antibody Assay as Diagnostic Tools in Subjects with Suspected Antibody DeficiencyMagdalena Dziadzio1,2*, Gabriela Barcenas Morales G4, Jennifer Harvey1, Roy Smith1, Joanna Lukawska2, Fariba Tahami1, Lourdes Ceron-Gutierrez3, Rainer Doffinger3, Suranjith Seneviratne1, Ronnie Chee1 and Helen Baxendale3
- *Corresponding Author:
- Magdalena Dziadzio
Department of Specialist Allergy and Clinical Immunology
University College London Hospitals, Royal Free Hospital, London
Tel: 0203 456 5242
E-mail: [email protected]
Received date: February 02, 2017; Accepted date: March 02, 2017; Published date: March 06, 2017
Citation: Dziadzio M, Morales GB, Harvey J, Smith R, Lukawska J, et al. (2017) Comparison of 23-Valent Pneumococcal IgG ELISA with Multiplex 13-Valent Serotype-Specific Antibody Assay as Diagnostic Tools in Subjects with Suspected Antibody Deficiency. J Mol Immunol 2:108.
Copyright: © 2017 Dziadzio M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The aim of this study was to compare the method agreement between the Pneumococcal 23vELISA (VaccZyme™, the Binding Site) and 13-valent serotype-specific multiplex assay in evaluating vaccination responses to Pneumovax® in patients with suspected antibody deficiency.
Diagnostic accuracy in antibody deficiencies is important as potential therapies are costly and lifelong. The literature regarding interpretation of results shows no consensus; this study was needed to guide our practice and to see if the multiplex assay is superior to 23vELISA or whether the two assays could be used together.
Pneumococcal antibody levels from a sample cohort of 64 patients referred to our Immunology Clinic for investigations of suspected immunodeficiency over the period of 6 month were analysed before and after testvaccination with Pneumovax® using both assays. There was good method agreement between ELISA and multiplex for serotype-specific individual IgG thresholds of 0.35 mg/l and 0.5 mg/l but not for 1.3 mg/l.
Thirteen patients had discordant results by the two methods. We propose that, the two assays studied could be used together to complement each other but prospective larger studies are needed to validate this. The vaccination results have to be interpreted with critical clinical judgement as meeting the “protective” antibody threshold is not a surrogate of function, especially in the context of immunodeficiency. We propose an in-house diagnostic flowchart for the assessment of vaccination responses.